ERBB2 and breast cancer: Expanding on this groundwork and addressing the limitations, our study aims to decouple the cell-type-specific effects to NAC response in the BC TME from transcriptomics alone by focusing on the HER2−negative (HER2−) patients, where NAC is recommended to increase the likelihood of achieving pCR following surgery, especially in triple negative breast cancer (TNBC) [43].